CancerDrs

Bladder Cancer clinical trials in Arkansas

23 actively recruiting bladder cancer trials at 6 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Arkansas:
  • Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
  • Highlands Oncology Group - Rogers — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…

Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…

Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in Arkansas:
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in Arkansas:
  • Arkansas Urology — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …

Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Sites in Arkansas:
  • Arkansas Urology, North Little Rock — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in Arkansas:
  • Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
  • Highlands Oncology Group - Rogers — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunothe…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06770582
Sites in Arkansas:
  • Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas
  • Highlands Oncology Group - Rogers — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in Arkansas:
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
  • Arkansas Urology — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…

Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in Arkansas:
  • Arkansas Urology — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…

Sponsor: Protara Therapeutics
NCT ID: NCT05951179
Sites in Arkansas:
  • Arkansas Urology — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissue…

Sponsor: Pfizer
NCT ID: NCT07421700
Sites in Arkansas:
  • Highlands Oncology Group, PA — Fayetteville, Arkansas
  • Highlands Oncology Group, PA — Rogers, Arkansas
  • Highlands Oncology Group, PA — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

People with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder. The standard treatment is to have chemotherapy, followed by surgery to completely remove the bladde…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07475806
Sites in Arkansas:
  • Arkansas Urology Associates — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Arkansas:
  • Highlands Oncology Group — Fayetteville, Arkansas
  • Highlands Oncology Group — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arkansas:
  • Massive Bio SYNERGY-AI site — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Industry

Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

BCDx is a urine-based multi-omic assay for early cancer recurrence detection in patients with a history of bladder cancer. This prospective, blinded study evaluates its efficacy in detecting recurrent NMIBC, offering a noninvasive monitori…

Sponsor: Early is Good Inc.
NCT ID: NCT05982561
Sites in Arkansas:
  • Arkansas Urology Research Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Industry

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07309445
Sites in Arkansas:
  • Arkansas Urology — Little Rock, Arkansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25